This transaction was disclosed through an SEC Form 8-K filing published on July 14, 2026, which serves as the primary source document for deal information. The deal has been announced, indicating that the parties have publicly confirmed the transaction, though no closing date or other timeline milestones have been disclosed.
On the acquirer side, Ligand Pharmaceuticals engaged Stifel as its lead financial advisor. Supporting Ligand's transaction efforts, Citi also served as a financial advisor to the acquirer. On the target side, XOMA Royalty Corp. retained Leerink Partners as a lead financial advisor and H.C. Wainwright & Co. as an additional financial advisor, ensuring that XOMA had dual representation throughout the transaction process.
No legal advisors have been disclosed in the available transaction documents.
The transaction is structured as a merger and acquisition in the healthcare sector. The total consideration is valued at $739 million; however, the specific composition of the consideration, whether paid in cash, stock, or a combination thereof, has not been disclosed. Similarly, the precise structure of the merger, including details about merger subsidiary structures or any earnout provisions, has not been publicly detailed in the available filings.
Key details that remain undisclosed include the expected closing date and timing, the breakdown of consideration by type and payment method, any financing arrangements or conditions precedent, material terms specific to the merger structure, and details regarding any regulatory filings or approvals that may be required. The sources do not specify whether any debt financing, equity financing, or other transaction financing has been arranged.